ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

May 30, 2003

CCOPs At Six Months: Sme Exceeding Patient Goals, Most Are Meeting Schedules

March 30, 1984

Letters to the Editor: Burzynski: Reviewers Sought To Discredit Antineoplaston Therapy

October 30, 1998

NCAB May Make Its Recommendation On Comprehensive Center Issues At September Meeting

August 5, 1988

NCI Resources, Services Available For Cancer Research

June 7, 1996

In Brief: SBA Writing Guidelines to Implement Act Giving 1.25 Percent Of R&D Budget To Small Business

July 23, 1982